RGEN Aug 2023 155.000 call
| Previous close | 15.70 |
| Open | 15.70 |
| Bid | 20.30 |
| Ask | 21.90 |
| Strike | 155.00 |
| Expiry date | 2023-08-18 |
| Day's range | 15.70 - 15.70 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
ZacksWhy Is CRISPR Therapeutics AG (CRSP) Up 1.8% Since Last Earnings Report?
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksQiagen (QGEN) Down 0.6% Since Last Earnings Report: Can It Rebound?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksWhy Is Repligen (RGEN) Up 2.7% Since Last Earnings Report?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GlobeNewswireRepligen Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at two upcoming investor conferences. William Blair’s 43rd Annual Growth Stock Conference being held in Chicago June 6-8. Tony J. Hunt, President and Chief Executive Officer, is scheduled to present a company overview on June 8, 2023 at 11:20 a.m. CT.Jefferies’ Global Healthcare Conference being hel
Simply Wall St.If EPS Growth Is Important To You, Repligen (NASDAQ:RGEN) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
ZacksRepligen (RGEN) Beats on Q1 Earnings, Lowers 2023 Guidance
Repligen's (RGEN) first-quarter earnings and revenues beat estimates.
ZacksRepligen (RGEN) Surpasses Q1 Earnings and Revenue Estimates
Repligen (RGEN) delivered earnings and revenue surprises of 8.47% and 0.91%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
Reports first quarter revenue of $182.7 million, with base business growth of 4% as reported and 7% at constant currencyReports first quarter gross margin of 55.2% on both GAAP and adjusted (non-GAAP) basisClosed on acquisition of single-use bag manufacturer FlexBiosys Inc. in April WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first fiscal quart
- Simply Wall St.
Should Weakness in Repligen Corporation's (NASDAQ:RGEN) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
With its stock down 18% over the past three months, it is easy to disregard Repligen (NASDAQ:RGEN). However, the...
ZacksWill AnaptysBio, Inc. (ANAB) Report Negative Q1 Earnings? What You Should Know
AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Motley FoolWhy Repligen Stock Is Sinking Today
Investors appear to be anticipating an underwhelming first-quarter report from the bioprocessing company.
ZacksRepligen (RGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Repligen (RGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Repligen to Report First Quarter 2023 Financial Results
Webcast and Conference Call to Be Held Tuesday, May 2, 2023, at 8:30 a.m. ETWALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2023 financial results on Tuesday, May 2, 2023. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- month reporting period ended March 31, 2023.The con
- Simply Wall St.
A Look At The Fair Value Of Repligen Corporation (NASDAQ:RGEN)
Key Insights The projected fair value for Repligen is US$157 based on 2 Stage Free Cash Flow to Equity With US$165...
ZacksWhy Is Repligen (RGEN) Down 11.4% Since Last Earnings Report?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
WALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 21-22. Tony J. Hunt, President and Chief Executive Officer, will participate in an analyst-led discussion on Tuesday, March 21, at 1:30 p.m. EDT. A live webcast of the presentation will be accessible through the Investor R
ZacksRepligen's (RGEN) Q4 Earnings and Revenues Beat Estimates
Repligen (RGEN) reports encouraging fourth-quarter and full-year 2022 results, with sales and earnings beating estimates.
- Simply Wall St.
Repligen Full Year 2022 Earnings: EPS Beats Expectations
Repligen ( NASDAQ:RGEN ) Full Year 2022 Results Key Financial Results Revenue: US$801.5m (up 20% from FY 2021). Net...
- Zacks
Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates
Repligen (RGEN) delivered earnings and revenue surprises of 17.24% and 0.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Repligen Reports Fourth Quarter and Full Year 2022 Financial Results
Fourth quarter revenue of $186.8 million represents year-over-year organic growth of 4% and 5% growth at constant currencyFull year revenue of $801.5 million represents year-over-year organic growth of 22% and 25% growth at constant currencyBase business organic growth was 35% in the fourth quarter and 39% for the full year WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported f
- Simply Wall St.
Why Repligen Corporation (NASDAQ:RGEN) Could Be Worth Watching
Let's talk about the popular Repligen Corporation ( NASDAQ:RGEN ). The company's shares led the NASDAQGS gainers with a...
GlobeNewswireRepligen Appoints Martin D. Madaus to Board of Directors
Martin Madaus Repligen Appoints Martin Madaus to Board of Directors WALTHAM, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences tools industry leader Martin D. Madaus. Dr. Madaus brings to the Repligen board over 25 years of industry experience, including five years as Chairman, President and Chief Executive Officer of Millipore Corporation, where he was integral to the company’s transformation in
- GlobeNewswire
Repligen to Report Fourth Quarter and Full Year 2022 Financial Results
Webcast and Conference Call to Be Held Wednesday, February 22, 2023 at 8:30 a.m. ESTWALTHAM, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2022 financial results on Wednesday, February 22, 2023. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the three- and twelve- month re
- Simply Wall St.
Repligen (NASDAQ:RGEN) stock performs better than its underlying earnings growth over last five years
Long term investing can be life changing when you buy and hold the truly great businesses. While not every stock...
ZacksModerna (MRNA) Soars 3.3%: Is Further Upside Left in the Stock?
Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
